Treatment she can plan on.

Clinical response was 63% (n=215) for CIMZIA patients with moderate-to-severe Crohn’s disease vs. 36% (n=210) for placebo patients, based on a 26-week study in which all patients received CIMZIA 400 mg at 0, 2, and 4 weeks, and week 6 responders were randomized to CIMZIA 400 mg or placebo every 4 weeks.1

For moderate-to-severe CD patients

CIMZIA® (certolizumab pegol) is indicated for reducing signs and symptoms of Crohn’s disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

NEXT: Patient Profile